Fujifilm and Taiho Pharmaceutical Enter into Strategic Partnership for Development of Next-Gen ADC Manufacturing Technologies

FUJIFILM Corporation and Taiho Pharmaceutical announced that they have entered into a strategic partnership agreement for the development of manufacturing technologies for next-generation antibody-drug conjugates. Under this partnership, the two companies will work to optimize manufacturing processes for ADC candidates being developed by Taiho Pharmaceutical using the AraLinQ™ technology of Araris Biotech AG, a subsidiary of Taiho Pharmaceutical. By combining Taiho Pharmaceutical’s expertise and capabilities in ADC drug discovery with Fujifilm’s process development and manufacturing technologies cultivated through its biologics CDMO* business, the companies aim to achieve stable production of high-quality ADCs and enhance their global competitiveness in the next-generation ADC field.

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib